Dr. Reddy’s Q3 net rose under 2% to ₹1,404.2 cr., acquired NRT portfolio buoys revenue
Dr. Reddy's Laboratories reports modest profit growth, driven by global generics revenue and new product launches.
Dr Reddy's Labs Q3 Results: Profit grows 2% YoY to ₹1413 crore; revenue up 16%
Dr Reddy's Laboratories reported a 2% YoY increase in PAT to ₹1,413.3 crore for Q3 2024, driven by a 16% rise in revenue to ...
Is Philip Morris International (PM) the Best Sin Stock to Invest in 2025?
We recently published a list of 10 Best Sin Stocks to Invest in 2025. In this article, we are going to take a look at where Philip Morris International Inc. (NYSE:PM) stands against other best sin ...